tiprankstipranks
Chugai Pharmaceutical Co Ltd (CHGCF)
OTHER OTC:CHGCF

Chugai Pharmaceutical Co (CHGCF) Income Statement

13 Followers

Chugai Pharmaceutical Co Income Statement

Last quarter (Q3 2022), Chugai Pharmaceutical Co's total revenue was ¥225.28B, a decrease of -21.58% from the same quarter last year. In Q3, Chugai Pharmaceutical Co's net income was ¥67.80B. See Chugai Pharmaceutical Co’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
¥ 1.14T¥ 999.76B¥ 786.95B¥ 686.18B¥ 579.79B¥ 534.20B
Cost of Revenue
¥ 373.90B¥ 338.15B¥ 273.46B¥ 266.07B¥ 262.85B¥ 254.17B
Gross Profit
¥ 769.82B¥ 661.61B¥ 513.48B¥ 420.11B¥ 316.94B¥ 280.03B
Operating Expense
¥ 246.92B¥ 239.72B¥ 212.25B¥ 209.52B¥ 192.62B¥ 181.09B
Operating Income
¥ 522.89B¥ 421.90B¥ 301.23B¥ 210.60B¥ 124.32B¥ 98.93B
Net Non Operating Interest Income Expense
¥ -363.00M¥ 28.00M¥ -1.54B¥ 420.00M¥ 338.00M¥ -197.00M
Other Income Expense
------
Pretax Income
¥ 520.39B¥ 419.38B¥ 298.19B¥ 207.89B¥ 121.45B¥ 97.03B
Tax Provision
¥ 149.60B¥ 116.39B¥ 83.45B¥ 50.33B¥ 28.37B¥ 23.49B
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
¥ 370.79B¥ 303.00B¥ 214.73B¥ 157.56B¥ 92.49B¥ 72.71B
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
¥ 620.82B¥ 577.86B¥ 485.72B¥ 475.59B¥ 455.46B¥ 435.26B
Net Income From Continuing And Discontinued Operation
¥ 370.79B¥ 303.00B¥ 214.73B¥ 157.56B¥ 92.49B¥ 72.71B
Normalized Income
¥ 370.79B¥ 303.00B¥ 214.73B¥ 157.56B¥ 92.49B¥ 72.71B
Interest Expense
¥ 56.00M¥ 48.00M¥ 62.00M¥ 125.00M¥ 111.00M¥ 110.00M
EBIT
¥ 520.45B¥ 419.43B¥ 298.25B¥ 208.02B¥ 121.56B¥ 97.14B
EBITDA
¥ 520.45B¥ 419.43B¥ 298.25B¥ 208.02B¥ 121.56B¥ 97.14B
Currency in JPY

Chugai Pharmaceutical Co Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis